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LETTER TO THE EDITOR
Hyperbilirubinaemia in patients treated with recombinant human
interleukin-2 (rIL-2)
Sir - Thus far, we have treated 22 patients with rIL-2 (Cetus,
Emeryville, CA, USA) alone, with chemotherapy or with ex
vivo rIL-2 activated lymphocytes (LAK). Each protocol com-
prised continuous infusion of rIL-2: 3 MU m-2 day-' for five
consecutive days with treatment intervals of 1-3 weeks. We
observed transient hyperbilirubinaemia above 50 Lmol 1'
(>3 mgdl-'; WHO grade >2) in three patients (16%),
which is in accordance with the literature (West et al., 1987).
Notably, this side-effect occurred in the first treatment cycle,
and did not recur in the second or third cycle. In these three
patients, maximum bilirubin concentration in the first cycle
was 59, 87 and 109ptmol 1`, respectively. In subsequent
cycles, the median value of peak bilirubin concentration was
14tLmol 1' (range 10-48). In 19 patients without hyper-
bilirubinaemia grade >2, the median value of peak concen-
tration was 20Amol 1-' (range 9-49) in the first cycle, and in
no patient of this group did the bilirubin concentration rise
above 50timol -' during subsequent cycles.
One patient with hyperbilirubinaemia consented to a liver
biopsy. We report our findings, since such histological
examinations have not been published yet. It concerns a
65-year-old woman with lymph node metastases of
melanoma, who was treated with sequential rIL-2 and dacar-
bazine (DTIC). Co-medication consisted of acetaminophen
500 mg orally, 6 times daily, given routinely. During rIL-2
treatment the total bilirubin concentration rose to a maxi-
mum of 109 1amol 1-' (normal <20), conjugated bilirubin
79gimol 1' (<5), alkaline phosphatase 476 U 1-l (<80),
gamma-GT 96U1'- (<18), ASAT 42U 1- (<30) and
ALAT 95 U 1- (< 30). Before the administration of DTIC, a
liver biopsy was performed. Although architecture of the
liver was preserved, microscopic examination showed ne-
crosis in periportal areas, and moderate to severe
inflammation manifested by infiltration of lymphocytes in
portal and periportal areas and sinusoids. This is in agree-
ment with findings in animal studies (Matory et al., 1985).
We also found an increased number of eosinophilic
granulocytes. Immunohistochemistry showed that these
infiltrating lymphocytes were phenotypic CD2+, CD3 + and
CD45+, but CD22 - (B-cell marker). CD2+, CD3 +
lymphocytes were predominantly CD4+ (T-helper marker).
Only few CD8 + lymphocytes (cytotoxic T-cell marker) were
seen. Sporadically, Leul9+ lymphocytes were found in the
portal areas and sinusoids. Lymphocytes did not express
appreciable amounts of CD25 (IL-2 receptor) or HLA-DR.
Kuppfer cells showed a marked expression of CD4 and
CD25. These cells belong to the monocytic-histiocytic
lineage, and are reported to express CD4 (Poppema & de
Ley, 1985) and, after IL-2 stimulation, CD25 (Hancock et
al., 1987). In summary, microscopic examination of the liver
during rIL-2 induced hyperbilirubinaemia shows features of
acute multifocal hepatitis with necrosis and acute perichol-
angitis. We assume that this represents a non-specific toxic
event. In view of the fact that hyperbilirubinaemia does not
necessarily recur during subsequent rIL-2 cycles, we suggest
that hyperbilirubinaemia does not preclude further treatment
with rIL-2 at full dose.
Yours etc.,
C.J.A. Punt*, S.C. Henzen-Logmans,
R.L.H. Bolhuis & G. Stoter,
Dr Daniel den Hoed Cancer Centre,
Groene Hilledijk 301,
3075 EA Rotterdam,
The Netherlands.
*Present address: St Radboud University Hospital, Dept of Medical
Oncology, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
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